EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).

Studied

Clinical guideline covering prevention, diagnosis and treatment of fatty liver disease linked to metabolic risk factors.

Who / model

The guidance addresses adults with metabolic fatty liver disease, including people with type 2 diabetes or obesity.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

The guideline advises lifestyle changes and management of coexisting diabetes or obesity, including semaglutide or tirzepatide when indicated. It discusses resmetirom for adults with non-cirrhotic liver inflammation and significant scarring, subject to local approval.

Limits

The guideline states that no disease-targeted drug could then be recommended for the cirrhotic stage.

Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary